Risk-based criteria for deciding when pharmaceutical products require dedicated facilities, areas or equipment.
Dedicated manufacturing is a control measure, not a therapeutic-class label. The need for dedication follows from whether cross-contamination can be consistently controlled to an acceptable level.
Uncontrollable exposure
If cleaning, containment and organizational controls cannot reliably maintain contamination below the health-based limit, dedication may be necessary.
Highly sensitising materials
Some materials present hazards for which very small exposures can be clinically important and may not be adequately controlled by a conventional HBEL approach.
Analytical and cleaning feasibility
When the required residue limit cannot be reliably achieved or demonstrated, dedication can become a practical risk-control decision.
Risk-based documentation
The rationale should be documented as part of QRM rather than assumed from potency or product class alone.
Frequently asked questions
Does every low-HBEL product need a dedicated facility?
No. The ability of controls to manage the actual risk must be assessed.
Can inability to validate cleaning trigger dedication?
Yes, if the required level cannot be consistently achieved or demonstrated.
Are beta-lactam-related sensitization concerns special?
Yes. Highly sensitising materials can require specific controls beyond ordinary HBEL logic.
Should the decision be documented in QRM?
Yes.
